This is a news story, published by Yahoo Finance, that relates primarily to CRISPR Therapeutics news.
For more CRISPR Therapeutics news, you can click here:
more CRISPR Therapeutics newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
CRISPR Therapeutics. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest biotech stocks news, small biotech stock news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
CRISPRThe Motley Fool
•72% Informative
Three Motley Fool contributors think they've found biotech stocks that have the potential to become much larger.
Here's why they think CRISPR Therapeutics , Zealand Pharma , and Viking Therapeutic are monster stocks in the making to buy right now.
Author: Casgevy is the first approved gene-editing treatment that uses the CRisPR-Cas9 gene-ingiting technique that earned its creators a Nobel Prize .
Viking announced in 2023 that VK2809 had met the primary endpoint of its phase 2 study in significantly reducing liver fat content through 12 weeks of treatment.
Viking also has two programs in phase 1 testing -- an oral version of VK2735 that should soon advance to phase 2 , and VK0214 , which targets the rare genetic disorder X-linked adrenoleukodystrophy.
Viking's market cap right now is only $5.5 billion .
VR Score
63
Informative language
57
Neutral language
15
Article tone
formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
9
Source diversity
2
Affiliate links
no affiliate links